Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

End-of-day quote Nasdaq
Other stock markets
 03:30:00 21/06/2024 am IST 		5-day change 1st Jan Change
25.53 USD -1.28% Intraday chart for Dianthus Therapeutics, Inc. +1.07% +145.48%
12/06 Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy MT
12/06 Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial DJ

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target
MT
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating
MT
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating
MT
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target
MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating
MT
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target
MT
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate
MT
Raymond James Starts Dianthus Therapeutics at Outperform, $24 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. News Dianthus Therapeutics, Inc.
  5. Analyst Reco.